GlassScriptPhysician profile
Sheeba K Cherian
NPI 1417342874
$6,209.96
in general payments reported to CMS, 2019-2025
36 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $52.77 · 2021: $733 · 2022: $1,187 · 2023: $1,428 · 2024: $1,210 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $788.75 | 2021-2025 | Dupixent |
| Genzyme Corporation | $562.68 | 2021-2025 | |
| Pfizer INC. | $561.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $512.25 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Glaxosmithkline, LLC. | $509.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $386.78 | 2021-2025 | Fasenra, Tezspire, Evusheld |
| Octapharma USA, INC. | $339.97 | 2021-2025 | Octagam Immune Globulin (Human), Panzyga, Cutaquig |
| Csl Behring | $319.55 | 2022-2025 | Hizentra, Privigen |
| Novartis Pharmaceuticals Corporation | $280.09 | 2021-2025 | |
| Genentech USA, INC. | $224.52 | 2023-2025 | Xolair |
| Kaleo, INC. | $210.43 | 2020-2024 | Auvi-Q |
| Grifols USA, LLC | $194.18 | 2020-2025 | Xembify, Gamunex-C |
| Optinose US, INC. | $156.87 | 2019-2025 | |
| Amgen INC. | $121.98 | 2021-2025 | Tezspire |
| Blueprint Medicines Corporation | $109.65 | 2023-2024 | Ayvakit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $92.19 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $84.93 | 2021-2022 | |
| Hospira, INC. | $70.09 | 2024-2025 | |
| Pharming Healthcare, INC. | $66.87 | 2022-2025 | Ruconest |
| Organon LLC | $65.13 | 2025 | Vtama |
| Azurity Pharmaceuticals, INC. | $60.30 | 2025 | Alvesco |
| Phadia US INC. | $59.19 | 2021-2023 | Immunocap |
| Gc Biopharma USA, INC. | $54.62 | 2024-2025 | Alyglo, Alyglo |
| Leo Pharma INC. | $48.44 | 2025 | Adbry, Anzupgo |
| Kedrion Biopharma, INC. | $47.53 | 2024 | Gammaked, Koate, Albuked |
| Sanofi-Aventis U.S. LLC | $42.71 | 2020-2021 | |
| Covis Pharma Gmbh | $42.01 | 2022 | |
| Tersera Therapeutics LLC | $35.82 | 2023 | Quzyttir |
| Ani Pharmaceuticals, INC. | $28.93 | 2023 | Purified Cortrophin Gel |
| Insmed, INC. | $22.87 | 2025 | Arikayce |
| Biocryst US Sales Co., LLC | $21.62 | 2023 | Orladeyo |
| Alk-Abello, INC | $21.52 | 2022 | |
| Merck Sharp & Dohme LLC | $20.46 | 2021 | |
| Ionis Pharmaceuticals, INC. | $17.42 | 2025 | |
| Hikma Pharmaceuticals USA | $15.73 | 2023 | Ryaltris |
| Horizon Therapeutics Plc | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheeba Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.